Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Seno Medical Instruments Receives European Approval for Imagio Technology - Medical Product Outsourcing
OEM News

Seno Medical Instruments Receives European Approval for Imagio Technology

Technology designed to improve breast cancer diagnostics.

Seno Medical Instruments Inc. has received the CE Mark for its Imagio opto-acoustic imaging system, which could give the San Antonio, Texas-based device company market penetration for its medical device in Europe.

The Imagio technology is designed to improve the process of diagnosing breast cancer, eliminating the need for intrusive biopsies for some patients.

Seno currently is engaged in a pivotal study to determine the effectiveness of its technology.

“Experts recently presented data from the Imagio feasibility study at the European Congress of Radiology in Vienna, and it was enthusiastically received by European key opinion leaders,”Seno CEO Janet Campbell said about the company’s Imagio technology. “The CE Mark means we can now commercialize this new breast imaging system in Europe, and it gives us the opportunity to continue developing our relationships with physicians and regulators in the EU.”

Each year, millions of women around the world undergo core needle or surgical breast biopsies after a suspicious mass is found through breast imaging or self-exams. Seno officials say studies show that more than 80 percent of these biopsies reveal benign pathology after they are analyzed in a laboratory.

The Imagio Pivotal Study is ongoing in the United States. It involves 16 hospitals and imaging centers throughout the country. The study will form the basis of the company’s pre-market approval application to seek approval from the U.S. Food and Drug Administration for its technology.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters